Next Generation Sequencing
Support and Educational Content

Towards providing personalized medicine—considerations for reliable NGS data

Scientists at Geneseeq Technology, Inc. share insights into how target capture can be improved for accurate clinical diagnostics by using optimized blocking oligos and stringent hybridization conditions

Geneseeq is a cancer diagnostics company that provides treatment solutions based on comprehensive, systematic analysis of patients’ genomic mutations. The company mission is to bring precision care to cancer patients through a combination of next generation sequencing (NGS) and an up-to-date cancer knowledge base. As of March 2014, the company had guided treatment decisions for approximately 300 patients.


Geneseeq was founded in 2008 by a group of postdoctoral researchers from University of Toronto, Canada, and Stanford University, CA, USA. Geneseeq headquarters and R&D team are based in the MaRS Discovery District in Toronto. The bioinformatics department is located in Stanford University. In 2013, the company’s Asia office was established in Nanjing, China, and is now Geneseeq’s largest facility, with 10,000 ft2 lab space and 15 scientists.

Choosing target capture technology

The founding members of Geneseeq were IDT customers during their graduate research studies, and they have continued using IDT products since forming the company. The products they have used range from primers for PCR and long DNA fragments to, more recently, NGS xGen® Lockdown® Probes and xGen Blocking Oligos for target capture. Geneseeq scientists use these target capture probes to sequence specific regions of the cancer genome. The resulting data helps clinicians make informed decisions about which therapies are suitable for individual patients, what is known as “personalized medicine”.

The clinical diagnostics field recognizes that there are only several hundred genes in the human genome that can be targeted for cancer treatment. The current trend is to selectively sequence these actionable genes. Methods for isolating these genes from the entire genome have, until recently, been challenging. The scientists at Geneseeq have used both solid phase–based array methods (e.g., Roche NimbleGen SeqCap®), and solution-based probe methods (e.g., Agilent SureSelect® and Illumina TruSeq®). They settled on xGen Lockdown Probes from IDT because these probes offer unique advantages that other kits do not:

  • Scalability—ability to adjust the number of reactions needed;
  • Flexibility—ability to alter the number of enriched genes per reaction; and
  • Capacity for optimization—introduce single additional probes as necessary

Target capture method

Geneseeq was an early adopter of xGen Lockdown Probes and undertook protocol optimization over the first year and a half of use. They tried different hybridization buffers and temperatures, and compared different blocking oligonucleotide sequences. The scientists also tested a variety of sample types: formalin-fixed, paraffin-embedded (FFPE), fresh and frozen tissue, and blood.

Overcoming FFPE samples. Most cancer specimens are formalin-fixed and paraffin-embedded (FFPE), a process that causes varying degrees of DNA damage, depending on the pathology processing protocol and the age of the sample. Typically, FFPE samples are notorious for yielding low quantity and quality nucleic acid, resulting in less effective library construction and low PCR efficiency during library amplification.

Important considerations for working with FFPE tissue are:

  1. Pre-enrichment:
    1. Method of DNA extraction,
    2. Method of DNA fragmentation, and
    3. Method of library construction.
  2. Enrichment:

    Sample ratios for multiplexing; e.g., ratios for pooling different libraries of variable DNA quality, ratios for libraries when combining FFPE samples with fresh or frozen tissue or with blood samples.

    This is critical because the efficiency of PCR is different when using DNA isolated from FFPE samples than when the DNA comes from blood/tissue samples. To attain the desired coverage for every sample within a multiplex pool, it is important that library input from different sources be adjusted to overcome any difference in PCR efficiency during post-capture amplification.

  3. Post-capture amplification:

    Maximum recovery of the captured library and minimization of PCR cycles for post-capture amplification are required to reduce PCR duplication and bias in downstream NGS.

Geneseeq scientists have developed sophisticated guidelines for working with FFPE samples to ensure uniformity of coverage and consistent quality across samples. In their experience, xylene works best for dissolving paraffin in FFPE tissue sections. They also heat samples at 90°C for 1 hr after proteinase K digestion. This step helps to reverse formaldehyde modification of nucleic acids. Commercial DNA repair kits also help to improve library quality. At Geneseeq, the researchers use PreCR® Repair Mix (NEB) to repair a broad range of DNA damage, including mutations and PCR-blocking modifications.

Choice of hybridization and wash buffer. In initial experiments, Geneseeq scientists used the IDT xGen® Target Capture Protocol v1.0 (Protocol for DNA Probe Hybridization and Target Capture Using an Illumina Library) that included a 48-hour hybridization step. However, they discovered that SSC in the post-capture wash buffer inhibited subsequent on-bead PCR amplification. The researchers then tried the updated protocol, xGen® Lockdown® Probes Rapid Protocol for DNA Probe Hybridization and Target Capture Using an Illumina TruSeq® or Ion Torrent® Library Version 1.0, which incorporated a 4-hour hybridization at 47°C using the SeqCap® EZ Hybridization and Wash Kit (NimbleGen). They optimized target capture by comparing data obtained from hybridization at different temperatures and found that hybridization at 65°C resulted in greater enrichment for genes of interest (Figure 1).

Figure 1. Hybridization at higher temperature increases enrichment efficiency. Target capture was performed using xGen® Lockdown® Probes and SeqCap® EZ Hybridization and Wash kit (NimbleGen). Hybridization was performed for 4 hr at 47°C or 65°C, as indicated. Relative levels of 3 target genes after enrichment were measured by real-time qPCR using primers targeting the enriched exon fragments. Relative fold enrichment was calculated by normalizing the relative level of targeted gene fragments to the prehybridization library DNA concentration.

To minimize loss of captured DNA during elution and purification steps, and to shorten the duration of steps before actual sequencing, they also performed on-bead, post-capture PCR amplification. On-bead PCR was not inhibited by the presence of residual wash buffer when the SeqCap wash kit was used. Additionally, similar or greater enrichment of target genes was obtained for on-bead PCR than for PCR performed after elution (Figure 2).

Figure 2. On-bead post-capture PCR amplification enhances enrichment. Target capture was performed using xGen® Lockdown® Probes and SeqCap® EZ Hybridization and Wash kit (NimbleGen). Post-capture PCR amplification was performed either on-bead or on captured DNA eluted from beads by boiling at 98°C for 10 min. Relative levels of 3 target genes after enrichment were measured by qPCR, using primers targeting the enriched exon fragments. Relative fold enrichment was calculated by normalizing the relative level of targeted gene fragments to the prehybridization library DNA concentration.

Choice of blocking oligos. Geneseeq scientists first used IDT xGen Standard Blocking Oligos for Illumina TruSeq and Other Single-Index Adapters. When IDT launched xGen Universal Blocking Oligos, in which a single blocking oligo can effectively block multiple barcoded adapters, Geneseeq performed a thorough comparison of the two IDT blocking oligo products. The researchers found that, for their purposes, the Universal Blocking Oligos were more efficient at reducing background (off-target rate), leading to enhanced enrichment (on-target rate) (Figures 3 and 4).

Figure 3. xGen® Universal Blocking Oligos increase enrichment efficiency. Target capture was performed using xGen Lockdown® Probes and different IDT hybridization protocols with xGen Standard or Universal Blocking Oligos, as indicated. Relative levels of 3 target genes were measured by real-time qPCR using primers targeting enriched exon fragments and normalizing to the relative level of total enriched library measured by qPCR using p5 and p7 primers (Illumina). Fold enrichment was calculated by normalizing the relative level of targeted gene fragments to their own relative levels in prehybridization samples (Prehyb). The data show that using Universal Blocking Oligos significantly enhanced enrichment compared to Standard Blocking Oligos. Additionally, combining Universal Blocking Oligos with the xGen Rapid Capture Protocol (NimbleGen buffers; 4 hr hybridization at 65°C) provides up to 5X greater enrichment than the original 48 hr hybridization protocol (IDT buffers) used with Standard Blocking Oligos.

Negative controls. For negative controls, Geneseeq scientists use genes, ACTB (β-actin) and GAPDH, not included in their target enrichment panels. The researchers were very impressed with the performance of the xGen Lockdown Probes. They found that immediately after library preparation, they were able to detect the negative controls by qPCR, but after enrichment with xGen Lockdown Probes, when combined with Universal Blocking Oligos and with use of the xGen Rapid Capture Protocol, there was no trace of these amplicons (Figure 4). This demonstrated how effectively the negative controls were depleted by enrichment and indicated that the off-target rate is low.

Figure 4. xGen® Universal Blocking Oligos reduce off-target rates. Target capture was performed using xGen Lockdown® Probes with different hybridization protocols and xGen Standard or Universal Blocking Oligos, as indicated. The presence of negative control genes, (A) ACTB and (B) GAPDH, was measured by qPCR using primers targeting the negative control gene fragments and normalizing to the relative level of total enriched library measured by qPCR using p5 and p7 primers (Illumina). Fold enrichment was calculated by normalizing the relative level of control genes after PCR to their relative levels in prehybridization samples (Prehyb). The data show that combining Universal Blocking Oligos with the xGen Rapid Capture Protocol (NimbleGen buffers; 4 hr hybridization at 65°C) provides markedly better specificity compared to the original 48 hr hybridization protocol (IDT buffers) or Standard Blocking Oligos, indicated by the absence of negative control genes.

Performance of xGen Lockdown Probes

IDT xGen Lockdown Probes are individually assessed by mass spectrometry for QC. Geneseeq researchers found that use of these probes, together with the optimized target capture protocol, allowed them to achieve >80% on-target rate with very high uniformity of coverage for different genes. The researchers compared xGen Lockdown Probes to other commercially available target capture reagents and discovered that panels comprising Lockdown Probes combined in a 1:1 molar ratio delivered, on average, ~40% better enrichment efficiency compared to the other reagents.

Sequencing platforms

Initially, the scientists used the SOLiD sequencing system (Applied Biosystems). However, since 2010, they have been using Illumina sequencing platforms, starting with the HiSeq® 2000 instrument, and now the HiSeq® 2500 instrument for sequencing larger genomes, such as the human exome. For clinical assays, the scientists use the MiSeq® system. They have chosen to use the MiSeq system, rather than HiSeq, because the former provides sufficient throughput for their gene panel and produces higher quality sequencing data with longer read lengths in a short period of time. Furthermore, the MiSeq System is the first and only NGS system for in vitro diagnostics approved by the US Food and Drug Administration (FDA). More recently, Geneseeq has been investigating the new NextSeq® 500 system (Illumina) that allows higher throughput and the flexibility to fulfill their growing clinical diagnostics needs.

From R&D to clinical diagnostics

Geneseeq scientists use xGen Lockdown Probes for both research and product development in their labs in Toronto and Stanford. The optimized probe sets and protocols are then used by their clinical diagnostics service lab in Nanjin, to serve the Asian market. They have tested >300 patients in the last year and are following the progress of some of these patients for whom the tests suggested a particular targeted therapy. By accumulating diagnosis and treatment information from large patient numbers, the Geneseeq scientists are generating sufficient data to provide statistical significance to their tests in clinical practice.

Researcher profile

Yang Shao, Founder, CEO, and Member of the Board Directors, Geneseeq, is a cancer biologist and bioinformatician. He received his bachelor’s degree in immunology and biochemistry from the University of Toronto, Canada, and has been working on cancer driver gene discovery and diagnostics since 2006. Yang Shao began studying cancer genomics early in his research career, using whole genome landscape profiling methods, initially SNP and gene expression arrays, and since 2008, next generation sequencing methods. Together with other colleagues, he founded Geneseeq in 2008. He has publications in several peer reviewed journals and is a contributing author to chapters in several cancer biology textbooks. His main interest is in accelerating the use of NGS in the clinic to increase societal benefit to patients.

Selected publications

Shimoda M, Principe S, et al. (2014) Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol, [epub ahead of print] doi: 10.1038/ncb3021.

Molyneux SD, Waterhouse PD, et al. (2014) Human somatic cell mutagenesis creates genetically tractable sarcomas. Nat Genet, 46:964–972.

Shao YW, Khokha R, et al. (2013) Tumor Progression and Metastasis. In: Tannock I, Hill R, et al (editors) The Basic Science of Oncology, Fifth Edition McGraw-Hill International Editions. p 219–242.

Murthy A, Shao YW, et al. (2012) Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis. J Immunol, 188(6):2876–83.

Murthy A, Shao YW, et al. (2012) Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity, 36(1):105–19.

Xue Wu, Director, Research and Development, is a molecular biologist with specialization in signal transduction and cancer biology. She obtained her bachelor’s degree in biological sciences in China and a master’s degree from Dalhousie University, Halifax, Canada, where she investigated molecular mechanisms of mammary gland development and tumorigenesis. Subsequently, she worked at Atlantic Research Centre, Halifax, as a research assistant, studying colorectal cancer. She obtained her PhD from the University of Toronto, studying the molecular pathogenesis of human genetic syndromes caused by germline mutations. Her postdoctoral training was at the Ontario Cancer Institute, Canada, where she studied functional genomics and epigenomics of different cancers, including medulloblastoma, triple negative breast cancer, and lung cancer drug resistance. She has publications in several high impact journals.

Selected publications

Wu X, Yin J, et al. (2012) Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol, 32(19):3872–3890.

Wu X, Simpson J, et al. (2011) MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest, 121(3):1009–1025.

Marin TM, Keith K, et al. (2011) Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest, 121(3):1026–1043.

Yoo BH, Wu X, et al. (2010) Oncogenic ras-induced down-regulation of autophagy mediator Beclin-1 is required for malignant transformation of intestinal epithelial cells. J Biol Chem, 285(8):5438–5449.

Product focus: Target capture reagents

xGen® Lockdown® Probes—target capture probe pools for NGS

xGen Lockdown Probes are pools of individually synthesized, quality controlled, and normalized hybridization probes. Use them to generate custom capture panels for targeted sequencing to enhance the performance of existing panels. xGen Predesigned Gene Capture Probe Pools are available for any human RefSeq coding gene. Select from predesigned and custom probes that offer:

  • Sensitive detection of SNPs, indels, CNV, LOH, and translocations
  • GMP compliance for clinical and diagnostics research
  • Flexibility to augment existing panels or create completely custom panels
  • Quick delivery

Discover more about xGen Lockdown Probes.

xGen Lockdown Panels

xGen Lockdown Panels are preconfigured, validated, and stocked pools of xGen Lockdown Probes for targeted next generation sequencing of defined gene families:

  • xGen Exome Research Panel
  • xGen Acute Myeloid Leukemia Panel
  • xGen Pan-Cancer Panel
  • xGen Inherited Diseases Panel
  • xGen Human ID Research Panel
  • xGen Human mtDNA Research Panel

Discover more about xGen Lockdown Panels.

xGen Lockdown Reagents—hybridization and wash kit

xGen Lockdown Reagents have been optimized to deliver deep, even coverage of targets captured using xGen Lockdown Probes and Panels. Achieve uniform coverage with hybridization and wash buffers that are optimized for target enrichment using xGen Lockdown Probes and Panels. A short, 4-hour hybridization protocol generates results quickly.

Discover more about xGen Lockdown Reagents.

xGen Blocking Oligos

xGen Universal Blocking Oligos for single- or dual-index adapters used with common sequencing platforms improve on-target performance for multiplexed samples by reducing adapter participation in hybridization enrichment. Custom adapters can be manufactured for other barcodes or to meet the needs of customers who require specific modifications or services to improve performance in unique applications.

Discover more about xGen Blocking Oligos.

Additional reading

Read an overview article about target enrichment:

Target enrichment facilitates focused next generation sequencing—Understand the rationale and benefits of enriching subsets of the genome (target enrichment by hybrid capture) prior to sequencing. Use this strategy for genotyping, identifying splice variants and indels, and profiling genomic recombination events as well as viral and transposon integration sites.

Read other articles demonstrating use of target capture for focused NGS:

NGS target capture recommendations for FFPE samples—Webinar review: Learn about NGS library preparation and target capture from formalin-fixed, paraffin-embedded samples.

Advantages of high quality, probe-based gene capture panels—Target enrichment by hybrid capture lets you focus your genomic analysis on specific regions of interest, increasing depth of coverage of targeted sequences and improving the detection of rare genomic events. You can create custom human gene capture panels quickly and cost-effectively using IDT preconfigured pools of probes targeting the coding sequences (CDS) of human protein-coding genes, or with predesigned disease or exome panels.

Target Enrichment Identifies Mutations that Confer Fitness Effects—Researchers at the University of Texas use target enrichment with xGen® Lockdown® Probes and NGS to track frequency of mutations in evolving bacterial populations over a given time course and to gauge their importance based on their fitness effect.

Next Generation Sequencing in the Clinic: A Perspective from Dr Elaine Mardis, and Current Research at The Genome Institute—A discussion about the future of NGS in the clinic, and how the Genome Institute is using xGen® Lockdown® Probes for Targeted Sequencing.

Review other DECODED Online newsletter articles on NGS applications.

You can also browse our DECODED Online newsletter for additional application reviews, lab tips, and citation summaries to facilitate your research.

Author: Nicola Brookman-Amissah, PhD, is a Scientific Writer at IDT. © 2014, 2017 Integrated DNA Technologies. All rights reserved. Trademarks contained herein are the property of Integrated DNA Technologies, Inc. or their respective owners. For specific trademark and licensing information, see

xGen® Blocking Oligos

Adapter blocking oligos increase the number of on-target reads by preventing non-specific binding during hybridization.

Find blockers for your platform ≫

Related Articles

Target Enrichment Facilitates Focused Next Generation Sequencing

The rationale and benefits of enriching subsets of the genome (target enrichment by hybrid capture) prior to sequencing.

Read more ≫

Improving Uniform Coverage of Targeted Sequences for NGS

The challenges faced in obtaining uniform coverage of NGS data and how IDT xGen® Lockdown® Probes are uniquely positioned to facilitate uniform sequence coverage.

Read more ≫

Towards Providing Personalized Medicine—Considerations for Reliable NGS Data

Geneseeq Technology, Inc. demonstrates how they improved their target capture methods to increase accuracy in clinical diagnostics by using optimized blocking oligos and stringent hybridization conditions.

Read more ≫

Delivering Comprehensive Genomic Profiling for Clinical Cancer Care Using Targeted Sequencing

Read how scientists at Foundation Medicine, Inc use hybrid selection in their FoundationOne® Test to help clinicians select patient specific treatment options.

Read more ≫

Insertion Site Detection and Targeted RNA Capture Using Next Generation Sequencing

Scientists at Cofactor Genomics use in-solution hybridization to focus on regions of interest for next generation sequencing.

Read more ≫